Dr. Ruben Mesa Featured in Rare Diseases Report Magazine
MPN News | June 26, 2018
Dr. Mesa discusses updates on emerging innovations, his views about the greatest obstacles facing the treatment of rare diseases & his support for the working as a team when treating MPNs
Interferon Changes Life of Essential Thrombocythemia Patient, Karrie Schwartz
MPN News | June 25, 2018
Stories like Karrie's are the reason MPNRF is dedicated to investing time and resources into opportunities for repurposing existing drugs and figuring out the mechanisms of action that lead to results.
Screening for B cell clone prior to taking a JAK2 inhibitor suggested
MPN News | June 15, 2018
Austrian researchers find elevated risk for Lymphoma risk elevated in some with MF
HikeMF 2018 Raises $35,000 for MPN Research Foundation!
MPN News | June 8, 2018
The MPN Research Foundation is grateful to Julie, Lori and their team of volunteers who made this event possible. This year all proceeds benefit the MPN Research Foundationâ€™s Challenge Grants program!
MPNRF hosts meeting of the minds on the future of immunotherapy in MPN
MPN News | June 7, 2018
MPNRF hosts experts in the areas of MPN clinical practice, MPN research and immunotherapy with the goal to hear about ongoing work in the area of immunotherapy in MPNs.
Dr. Srdan Verstovsek presents results from Ropeginterferon vs Hydroxyurea study at MPN Asia 2018
MPN News | May 9, 2018
After a 2 year study, Ropeginterferon proves more effective than Hydroxyurea in symptom improvement and lowering progression rates
Free webinar for MPN patients and caregivers
MPN News | April 23, 2018
NCCN to host 2 events focused on education
myMPN data shows trends for PV, ET and MF
MPN News | April 16, 2018
Users with PV, ET and MF are entering symptom data across the country
Blood article by MD Anderson researchers looks back at 107 MF patients who discontinued Jakafi
MPN News | March 22, 2018
Authors describe epigenetic mutations in some patients and suggest follow up research is needed
CTI Biopharma expands it's clinical Trial
MPN News | March 1, 2018
CTI Biopharma is recruiting patients for the PAC203 study, a randomized phase 2 trial evaluating different doses of pacritinb in myelofibrosis patients. Previously, patients had to have a platelet count less than 100,000.
Recognizing some of the women in the MPN community
MPN News | March 6, 2018
March 8th is International Women's Day